Table 2.
Perioperative and pathology outcomes (n=100).
| Perioperative and pathology outcomes | Value |
|---|---|
| Estimated blood loss, median (Q1, Q3), mL | 100 (50, 150) |
| Operative time, median (Q1, Q3), min | 212.5 (188.0, 238.8) |
| Nerve-sparing, n (%) | 77 (77.0) |
| Lymphadenectomy, n (%) | 43 (43.0) |
| Intraoperative complications, n (%) | 0 (0) |
| Postoperative complications, n (%) | 16 (16.0) |
| Clavien-Dindo I | 12 (12.0) |
| Clavien-Dindo II | 2 (2.0) |
| Clavien-Dindo IIIa | 2 (2.0) |
| Length of stay, median (Q1, Q3), h | 5.6 (4.1, 21.9) |
| Pain medications discharge, n (%) | 53 (53.0) |
| NSAIDs | 49 (49.0) |
| Opioids | 4 (4.0) |
| Readmission, n (%) | 6 (6.0) |
| Foley catheter, median (Q1, Q3), day | 3 (3, 4) |
| Specimen weight, median (Q1, Q3), g | 40.0 (35.0, 49.5) |
| Extra-prostatic extension, n (%) | 38 (38.0) |
| Bladder neck invasion, n (%) | 6 (6.0) |
| Lymphovascular invasion, n (%) | 7 (7.0) |
| Seminal vesicle invasion, n (%) | 7 (7.0) |
| Positive margin, n (%) | 15 (15.0) |
NSAIDs, nonsteroidal anti-inflammatory drugs.